Can the booster interval for the tick-borne encephalitis (TBE) vaccine ‘FSME-IMMUN’ be prolonged? — A systematic review

Steffen, Robert; Erber, Wendy N.; Hj, Schmitt

doi:10.1016/j.ttbdis.2021.101779

Cited by 19 publications

(18 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…VE dropped to 88.6% for last dose > 10 years. Finding that VE at ≥ 3 doses persists for ≤ 10 years or longer agrees with seropersistence studies, finding mostly high seropositivity rates at ≥ 4 doses after 10 years 27 , 28 . Lasting immunity may also relate to rapid secondary antibody response 27 .…”

Section: Discussionsupporting

confidence: 82%

“…Finding that VE at ≥ 3 doses persists for ≤ 10 years or longer agrees with seropersistence studies, finding mostly high seropositivity rates at ≥ 4 doses after 10 years 27 , 28 . Lasting immunity may also relate to rapid secondary antibody response 27 . Our results support the extension of booster intervals to 10 years also in Germany, as under discussion elsewhere 27 and already implemented in Switzerland and Finland, without observed increases in VBIs 29 .…”

Section: Discussionsupporting

confidence: 82%

“…Lasting immunity may also relate to rapid secondary antibody response 27 . Our results support the extension of booster intervals to 10 years also in Germany, as under discussion elsewhere 27 and already implemented in Switzerland and Finland, without observed increases in VBIs 29 .…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Tick-borne encephalitis vaccine effectiveness and barriers to vaccination in Germany

Nygren

Pilic

Böhmer

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Tick-borne encephalitis (TBE) vaccination coverage remains low in Germany. Our case–control study (2018–2020) aimed to examine reasons for low vaccine uptake, vaccine effectiveness (VE), and vaccine breakthrough infections (VBIs). Telephone interviews (581 cases, 975 matched controls) covered vaccinations, vaccination barriers, and confounders identified with directed acyclic graphs. Multivariable logistic regression determined VE as 1—odds ratio with 95% confidence intervals (CI). We additionally calculated VE with the Screening method using routine surveillance and vaccination coverage data. Main vaccination barriers were poor risk perception and fear of adverse events. VE was 96.6% (95% CI 93.7–98.2) for ≥ 3 doses and manufacturer-recommended dosing intervals. Without boosters, VE after ≥ 3 doses at ≤ 10 years was 91.2% (95% CI 82.7–95.6). VE was similar for homologous/heterologous vaccination. Utilising routine surveillance data, VE was comparable (≥ 3 doses: 92.8%). VBIs (n = 17, 2.9% of cases) were older, had more comorbidities and higher severity than unvaccinated cases. However, only few VBIs were diagnostically confirmed; 57% of re-tested vaccinated cases (≥ 1 dose, n = 54) proved false positive. To increase TBE vaccine uptake, communication efforts should address complacency and increase confidence in the vaccines’ safety. The observed duration of high VE may inform decision-makers to consider extending booster intervals to 10 years.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionsupporting

confidence: 82%

See 1 more Smart Citation

Tick-borne encephalitis vaccine effectiveness and barriers to vaccination in Germany

Nygren

Pilic

Böhmer

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The median time to vaccine failure did not, however, differ between cases having received three doses or those having received more than four doses (not shown), suggesting no impact of adding an additional dose. It should also be noted that we did not observe appreciable differences in overall VE or VE over time between age groups (in agreement with findings summarised in a recent systematic review of TBE vaccine booster intervals25).…”

Section: Discussionsupporting

confidence: 93%

Retrospective, matched case–control analysis of tickborne encephalitis vaccine effectiveness by booster interval, Switzerland 2006–2020

et al. 2022

View full text Add to dashboard Cite

ObjectiveTo estimate effectiveness of tickborne encephalitis (TBE) vaccination by time interval (<5, 5–10 and 10+years) postvaccination.DesignA retrospective, matched case–control studyParticipantsCases—all adult (age 18–79) TBE cases in Switzerland reported via the national mandatory disease reporting surveillance system from 2006 to 2020 (final n=1868). Controls—community controls from a database of randomly selected adults (age 18–79) participating in a 2018 cross-sectional study of TBE vaccination in Switzerland (final n=4625).Primary outcome measuresFor cases and controls, the number of TBE vaccine doses received and the time since last vaccination were determined. Individuals were classified as being ‘unvaccinated’ (0 doses), ‘incomplete’ (1–2 doses) or ‘complete’ (3+ doses). Individuals with ‘complete’ vaccination were further classified by time since the last dose was received (<5 years, 5–10 years or 10+ years). A conditional logistic regression model was used to calculate vaccine effectiveness (VE: 100 × [1−OR]) for each vaccination status category.ResultsVE for incomplete vaccination was 76.8% (95% CI 69.0% to 82.6%). For complete vaccination, overall VE was 95.0% (95% CI 93.5% to 96.1%). When the most recent dose was received <5 years prior VE was 91.6% (95% CI 88.4% to 94.0%), 95.2% (95% CI 92.4% to 97.0%) when the most recent dose was received 5–10 years prior, and 98.5% (95% CI 96.8% to 99.2%) when the most recent dose was received 10+ years prior.ConclusionsThat VE does not decrease among completely vaccinated individuals over 10+ years since last vaccination supports the longevity of the protective response following complete TBE vaccination. Our findings support the effectiveness of 10-year TBE booster intervals currently used in Switzerland.

show abstract

“…Indeed, in Switzerland and Finland, evidence showing that high vaccine effectiveness remained for more than 10 years following a three-dose primary series led to the adoption of a 10-year booster interval, with the hope that this may increase vaccine uptake [ 23 , 77 ].…”

Section: Vaccine Uptakementioning

confidence: 99%

Recommendations to Improve Tick-Borne Encephalitis Surveillance and Vaccine Uptake in Europe

et al. 2022

View full text Add to dashboard Cite

There has been an increase in reported TBE cases in Europe since 2015, reaching a peak in some countries in 2020, highlighting the need for better management of TBE risk in Europe. TBE surveillance is currently limited, in part, due to varying diagnostic guidelines, access to testing, and awareness of TBE. Consequently, TBE prevalence is underestimated and vaccination recommendations inadequate. TBE vaccine uptake is unsatisfactory in many TBE-endemic European countries. This review summarizes the findings of a scientific workshop of experts to improve TBE surveillance and vaccine uptake in Europe. Strategies to improve TBE surveillance and vaccine uptake should focus on: aligning diagnostic criteria and testing across Europe; expanding current vaccine recommendations and reducing their complexity; and increasing public education of the potential risks posed by TBEV infection.

show abstract

Can the booster interval for the tick-borne encephalitis (TBE) vaccine ‘FSME-IMMUN’ be prolonged? — A systematic review

Cited by 19 publications

References 70 publications

Tick-borne encephalitis vaccine effectiveness and barriers to vaccination in Germany

Tick-borne encephalitis vaccine effectiveness and barriers to vaccination in Germany

Retrospective, matched case–control analysis of tickborne encephalitis vaccine effectiveness by booster interval, Switzerland 2006–2020

Recommendations to Improve Tick-Borne Encephalitis Surveillance and Vaccine Uptake in Europe

Contact Info

Product

Resources

About